Patents by Inventor José Ignacio Andrés-Gil

José Ignacio Andrés-Gil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12006302
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: June 11, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang
  • Patent number: 11820770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: November 21, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Publication number: 20220235062
    Abstract: The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Application
    Filed: February 7, 2022
    Publication date: July 28, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Michael A. LETAVIC, Jason C. RECH, Dale A. RUDOLPH, Akinola SOYODE-JOHNSON
  • Publication number: 20220213095
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 7, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Heather R. COATE, Meri DE ANGELIS, Curt A. DVORAK, Christine F. GELIN, Michael A. LETAVIC, Brad M. SAVALL, Akinola SOYODE-JOHNSON, Brice M. STENNE, Devin M. SWANSON
  • Publication number: 20220024896
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 27, 2022
    Inventors: José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang
  • Patent number: 11225478
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Patent number: 11168068
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: November 9, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Guy Maurits R. Bormans, Lieven Denis Herwig Declercq, Katleen Fierens, Joseph Elisabeth Leenaerts, Diederik Willem Elisabeth Moechars, Frederik Jan Rita Rombouts, Hartmuth Kolb, Wei Zhang
  • Publication number: 20210283277
    Abstract: The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue or a subject, in vitro or in vivo, and to precursors of said compounds.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 16, 2021
    Inventors: Diederik Willem Elisabeth MOECHARS, Frederik Jan Rita ROMBOUTS, Joseph Elisabeth LEENAERTS, José Ignacio ANDRéS-GIL, Katleen FIERENS, Vladimir CHUPAKHIN, Guy Mauritis R. BORMANS, Lieven Denis Herwig DECLERCQ, Hartmuth KOLB, Wei ZHANG
  • Patent number: 11045562
    Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Publication number: 20210177995
    Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Michiel Luc, Maria VAN GOOL, José Ignacio ANDRÉS-GIL, Manuel Jesús ALCÁZAR-VACA, Guy Maurits R. BORMANS, Sofie Jeanne Leopoldine CELEN, Joost VERBEEK
  • Patent number: 11033641
    Abstract: The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 15, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Patent number: 10967078
    Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: April 6, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Michiel Luc Maria Van Gool, José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen, Joost Verbeek
  • Publication number: 20200325138
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Publication number: 20200306389
    Abstract: The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 1, 2020
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Patent number: 10703749
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Publication number: 20200121677
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 23, 2020
    Applicant: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc, Maria Van Gool, Óscar Delgado-González, José Ignacio Andrés-Gil, Andrés Avelino Trabanco-Suárez
  • Patent number: 10604523
    Abstract: The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET).
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Peter Jacobus Johannes Antonius Buijnsters, Andrés Avelino Trabanco-Suárez, Meri De Angelis, Greta Constantia Peter Vanhoof, Jérôme Emile Georges Guillemont, Frederik Jan Rita Rombouts, Maarten Vliegen, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen
  • Patent number: 10584129
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 10, 2020
    Assignee: Janssen Pharmaceuticals NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu García-Molina, José Ignacio Andrés-Gil
  • Patent number: 10519162
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 31, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc Maria Van Gool, Maria Luz Martin-Martin, Susana Conde-Ceide, José Ignacio Andrés-Gil, Óscar Delgado-González, Gary John Tresadern, Andrés Avelino Trabanco-Suárez
  • Patent number: 10512646
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 24, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc Maria Van Gool, Óscar Delgado-González, José Ignacio Andrés-Gil, Andrés Avelino Trabanco-Suárez